Afficher la notice abrégée

Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy

dc.rights.licenseopenen_US
dc.contributor.authorDELAGREVERIE, H. M.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBAUDUIN, Claire
dc.contributor.authorDE CASTRO, N.
dc.contributor.authorGRINSZTEJN, B.
dc.contributor.authorCHEVRIER, M.
dc.contributor.authorJOUENNE, F.
dc.contributor.authorMOURAH, S.
dc.contributor.authorKALIDI, I.
dc.contributor.authorPILOTTO, J. H.
dc.contributor.authorBRITES, C.
dc.contributor.authorTREGNAGO BARCELLOS, N.
dc.contributor.authorAMARA, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.contributor.authorMOLINA, J. M.
dc.contributor.authorDELAUGERRE, C.
dc.date.accessioned2021-01-21T10:24:49Z
dc.date.available2021-01-21T10:24:49Z
dc.date.issued2020
dc.identifier.issn2328-8957 (Print) 2328-8957 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/25937
dc.description.abstractEnBackground In view of the fast viremia decline obtained with integrase inhibitors, we studied the respective effects of initiating efavirenz (EFV) or raltegravir (RAL)-based antiretroviral therapy (ART) regimens on human immunodeficiency virus (HIV)-1 deoxyribonucleic acid (DNA) levels and inflammation biomarkers in the highly inflammatory setting of advanced HIV-1 disease with tuberculosis (TB) coinfection. Methods We followed cell-associated HIV-1 DNA, high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), soluble CD14 and D-Dimer levels for 48 weeks after ART initiation in the participants to the ANRS12-180 REFLATE-TB study. This phase II open-label randomized study included ART-naive people with HIV and TB treated with rifampicin to receive RAL 400 mg twice daily (RAL400), RAL 800 mg twice daily (RAL800) or EFV 600 mg QD with tenofovir and lamivudine. Results In 146 participants, the median (interquartile range [IQR]) week (W)0 HIV-1 DNA level was 4.7 (IQR, 4.3–5.1) log10 copies/106 CD4+, and the reduction by W48 was −0.8 log10 copies/106 CD4+ on EFV, −0.9 on RAL400, and −1.0 on RAL800 (P = .74). Baseline median (IQR) hsCRP, IL-6, sCD14, and D-Dimer levels were 6.9 (IQR, 3.3–15.6) mg/L, 7.3 (IQR, 3.5–12.3) pg/mL, 3221 (IQR, 2383–4130) ng/mL, and 975 (IQR, 535–1970) ng/mL. All biomarker levels decreased over the study: the overall W0–W48 mean (95% confidence interval) fold-change on ART was 0.37 (IQR, 0.28–0.48) for hsCRP, 0.42 (IQR, 0.35–0.51) for IL-6, 0.51 (IQR, 0.47–0.56) for sCD14, and 0.39 (IQR, 0.32–0.47) for D-Dimers. There were no differences in biomarker reduction across treatment arms. Conclusions In participants with HIV and TB, EFV, RAL400, or RAL800 effectively and equally reduced inflammation and HIV-1 DNA levels.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectMORPH3Eus
dc.title.enImpact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy
dc.title.alternativeOpen Forum Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/ofid/ofz549en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32083147en_US
bordeaux.journalOpen Forum Infectious Diseasesen_US
bordeaux.pageofz549en_US
bordeaux.volume7en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03117487
hal.version1
hal.date.transferred2021-01-21T10:24:53Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Open%20Forum%20Infectious%20Diseases&rft.date=2020&rft.volume=7&rft.issue=2&rft.spage=ofz549&rft.epage=ofz549&rft.eissn=2328-8957%20(Print)%202328-8957%20(Linking)&rft.issn=2328-8957%20(Print)%202328-8957%20(Linking)&rft.au=DELAGREVERIE,%20H.%20M.&BAUDUIN,%20Claire&DE%20CASTRO,%20N.&GRINSZTEJN,%20B.&CHEVRIER,%20M.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_OFID_2020_Delagreverie.pdf
Taille:
290.8Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée